Mengis Capital Management’s Novo Nordisk NVO Stock Holding History

Mengis Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.36M	Sell	70,145 -219	-0.3%	-$9.41K	0.51%	54
2026 Q1	$2.59M	Buy	70,364 +3,670	+6%	+$174K	0.45%	61
2025 Q4	$3.39M	Buy	66,694 +50,154	+303%	+$2.56M	0.6%	45
2025 Q3	$918K	Buy	+16,540	New	+$968K	0.18%	110

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Mengis Capital Management's NVO Position: Q2 2026 in Review

Mengis Capital Management reduced its Novo Nordisk (NVO) stake by 0.31% in Q2 2026, selling an estimated $9.41K and leaving 70,145 shares worth $3.36M. The position accounts for 0.51% of the portfolio, ranked #54.

Mengis Capital Management first reported a position in NVO in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.39M in Q4 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Mengis Capital Management held 70,145 shares of Novo Nordisk worth $3.36M as of Q2 2026.
Mengis Capital Management sold 219 Novo Nordisk shares in Q2 2026, an estimated $9.41K.
Novo Nordisk made up 0.51% of Mengis Capital Management's portfolio in Q2 2026, its #54 holding.
Mengis Capital Management first reported a position in Novo Nordisk in Q3 2025 and has held it in 4 quarters since.
Mengis Capital Management's Novo Nordisk position peaked at $3.39M in Q4 2025.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Mengis Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.